Pneumococcal Vaccine Response in Alpha 1 Antitrypsin Deficiency and COPD
Tests a pneumococcal vaccine's immune response in adults with alpha 1 antitrypsin deficiency.
Plain-language title generated from the registry record
Registry title: Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
Key facts
- Where
- Birmingham, United StatesSee the site
- Phase
- Phase 4
Where in United States
- University of Alabama at BirminghamBirmingham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Alabama at Birmingham
- Trial code
- NCT07135427
- Record updated
- 27 October 2026
- Original description
The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections.Read full original descriptionShow less
Genetic Variation in IgG as a Mechanism for Immune Deficiency and Exacerbations in AATD
The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections.
To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.
Inclusion: Adults who are heterozygous for a SERPINA1 Z allele; Have either had no COPD exacerbations or 2 or more exacerbations in the previous year; Has not received a pneumococcal conjugate vaccine within the past 5 years, or has only received the pneumococcal polysaccharide vaccine in the past.
Exclusion: Received a pneumococcal conjugate vaccine within the past 5 years; Known allergy, severe adverse reaction, or other sensitivity to pneumococcal conjugate vaccines.